Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
|Slideshows|October 27, 2016
Depression Research Update: November 2016
Author(s)Mark L. Fuerst
Recent studies examine placebo responses to antidepressants, the effect of SSRIs on sleep in the elderly, and the best time of day for psychotherapy sessions.
Advertisement
View the information in PDF format.
References:
1. Furukawa TA, Cipriani A, Atkinson LZ, et al.
2. Tahir MA, et al.
3. Meuret AE, Rosenfield D, Bhaskara L, et al.
Advertisement
Related to this article
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
Phase 1 Data: SNTX-2643 Blunts the Brain's Stress Response After a Single Dose
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5